These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26986934)

  • 1. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
    Venkatesan S; Lamfers ML; Dirven CM; Leenstra S
    CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.
    Venkatesan S; Hoogstraat M; Caljouw E; Pierson T; Spoor JK; Zeneyedpour L; Dubbink HJ; Dekker LJ; van der Kaaij M; Kloezeman J; Berghauser Pont LM; Besselink NJ; Luider TM; Joore J; Martens JW; Lamfers ML; Sleijfer S; Leenstra S
    Oncotarget; 2016 Sep; 7(36):58435-58444. PubMed ID: 27533080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network pharmacology of glioblastoma.
    Aguda BD
    Curr Drug Discov Technol; 2013 Jun; 10(2):125-38. PubMed ID: 23237675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.
    Höland K; Salm F; Arcaro A
    Curr Cancer Drug Targets; 2011 Oct; 11(8):894-918. PubMed ID: 21861842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
    Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
    Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
    Bhusare N; Kumar M
    Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
    Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
    Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma.
    Su CC; Wang MJ; Chiu TL
    Int J Mol Med; 2010 Aug; 26(2):217-24. PubMed ID: 20596601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
    Haluska F; Pemberton T; Ibrahim N; Kalinsky K
    Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward precision medicine in glioblastoma: the promise and the challenges.
    Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
    Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targeted therapy of glioblastoma.
    Le Rhun E; Preusser M; Roth P; Reardon DA; van den Bent M; Wen P; Reifenberger G; Weller M
    Cancer Treat Rev; 2019 Nov; 80():101896. PubMed ID: 31541850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioblastoma--a moving target.
    Westermark B
    Ups J Med Sci; 2012 May; 117(2):251-6. PubMed ID: 22512247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using the molecular classification of glioblastoma to inform personalized treatment.
    Olar A; Aldape KD
    J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
    Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
    Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
    Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
    Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
    Lackner MR
    Expert Rev Mol Diagn; 2010 Jan; 10(1):75-87. PubMed ID: 20014924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging targeted therapies for glioma.
    Miller JJ; Wen PY
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma targeted therapy: updated approaches from recent biological insights.
    Touat M; Idbaih A; Sanson M; Ligon KL
    Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated network analysis identifies core pathways in glioblastoma.
    Cerami E; Demir E; Schultz N; Taylor BS; Sander C
    PLoS One; 2010 Feb; 5(2):e8918. PubMed ID: 20169195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.